Number of pages: 100 | Report Format: PDF | Published date: 08 September, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global sickle cell disease treatment market was pegged at ~US$ 2.3 billion in 2021 and is expected to witness a CAGR of ~15.3% during the forecast period.
Red blood cells (RBCs) with aberrant, rigid sickle shapes are the hallmark of sickle cell disease (SCD), a genetic blood illness brought on by mutations in the beta-globin gene. From person to person, the disease's severity varies greatly. This illness is characterized by a low level of red blood cells (anemia), recurrent infections, and cyclical pain episodes. The rising incidence of sickle cell illness is the main factor fueling the growth of the sickle cell treatment market.
The rising incidence of sickle cell illness is the main factor fueling the growth of the sickle cell treatment market. Additionally, rising R&D efforts, a strong pipeline, and a growing patient base are all anticipated to have an impact on the market expansion. The global market is anticipated to be driven by several factors, including an increase in immigration, better healthcare services, and a large population of people of African heritage. The market's expansion is also influenced by the approval of new products.
The growth of the market is, however, constrained by the high cost of the treatment. Patients stop taking their medication in the middle of dosage because of the expensive cost of this disease's lifelong treatment and a lack of reimbursement.
The global sickle cell disease treatment market has been analyzed from three perspectives: - treatment type, end user, and region.
Sickle Cell Disease Treatment Market by Treatment Type
Based on treatment type, the global sickle cell disease treatment market is segmented into, pharmacotherapy, bone marrow transplant, and blood transfusion. Over the course of the projected period, it is anticipated that the blood transfusion segment would expand stably. The increased demand for blood transfusions in sickle cell therapy and the rise in SCD prevalence are credited with driving this market segment's expansion. The ability to get normal red blood cells through blood transfusions increases hemoglobin levels to improve oxygen delivery in the body, lowering sickle cell anemia and the drive to produce more sickle cells. While bone marrow transplant (BMT) is the only treatment for sickle cell disease, hence the preference for this therapy option is increasing.
Sickle Cell Disease Treatment Market by End User
Based on the end user, the global sickle cell disease treatment market is divided into hospitals and specialty clinics. Vaso occlusive crisis is the primary factor driving sickle cell disease patients to hospitals, where the hospital segment leads the sickle cell disease treatment market.
Sickle Cell Disease Treatment Market by Region
Based on region, the global sickle cell disease treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the overall sickle cell disease treatment market, with the United States being the major contributor to the market. The growth in the region is attributed to improving access to sickle cell disease treatment and potential pipeline candidates. The United States' robust government support will encourage the market's healthy development even more. Additionally, increasing births with sickle cell disease in America will increase the demand for sickle cell treatment.
Some of the prominent players operating in the global sickle cell disease treatment market are: -